Chemical Namecapmatinib
Dosage FormTablets (oral; 150 mg, 200 mg)
Drug ClassKinase inhibitors
Approval Year2020


  • Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA approved test.
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tabrecta (capmatinib) Prescribing Information.2020Novartis Pharmaceuticals Corporation, East Hanover, NJ